This study is being conducted to test if injectable, long-acting anti-HIV drugs that are given every month can be used safely and effectively in individuals who are infected with HIV and who have had problems taking daily medications in the past. This study is also being conducted to evaluate how well are these study drugs tolerated.
   
The drugs being looked at in this study are oral cabotegravir, oral rilpivirine, long-acting injectable cabotegravir and long-acting injectable rilpivirine. A long-acting drug means it stays in the body much longer compared to the usual form of the drugs. Only oral rilpivirine is currently approved by the U.S. Food and Drug Administration (FDA) for treating HIV/AIDS in individuals who have never taken antiretroviral (ARV) drugs. Oral cabotegravir, long-acting cabotegravir and long-acting rilpivirine are experimental drugs.